3.54

0.56% -0.02

After Hours: 3.46 -0.08 -2.26%

Adc Therapeutics Sa (ADCT)

Overview News Price History Option Chain Discussions Forecast

Adc Therapeutics Sa stock is traded at $3.54, with a volume of 420.36K. It is down -0.56% in the last 24 hours and up +7.60% over the past month. ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Previous Close:

$3.56

Open:

$3.49

24h Volume:

420.36K

Relative Volume:

0.36

Market Cap:

$438.52M

Revenue:

$69.56M

Net Income/Loss:

$-240.05M

P/E Ratio:

-1.20

EPS:

-2.95

Net Cash Flow:

$-121.90M

1W Performance:

+1.14%

1M Performance:

+7.60%

6M Performance:

+24.21%

1Y Performance:

+82.47%

1-Day Range:

$3.49

$3.58

1-Week Range:

$3.38

$3.655

52-Week Range:

$1.05

$4.80

Adc Therapeutics Sa Stock (ADCT) Company Profile

Name

Adc Therapeutics Sa

Sector

Healthcare (1115)

Industry

Biotechnology (624)

Phone

41 21 653 02 00

Address

BIOPOLE, EPALINGES

Employee

263

Twitter

Next Earnings Date

2025-03-21

Latest SEC Filings

ADCT's Discussions on Twitter

Compare ADCT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADCT Adc Therapeutics Sa	3.54	441.00M	69.56M	-240.05M	-121.90M	-2.95
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-08-24	Initiated	Stephens	Overweight
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-06-22	Initiated	CapitalOne	Overweight
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral
Sep-21-22	Initiated	JP Morgan	Overweight
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-21	Initiated	Wolfe Research	Outperform
Aug-17-21	Resumed	Jefferies	Buy
Aug-09-21	Initiated	RBC Capital Mkts	Outperform
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight
Dec-03-20	Initiated	Stifel	Hold
Oct-29-20	Initiated	H.C. Wainwright	Buy
Jun-09-20	Initiated	BofA/Merrill	Buy
Jun-09-20	Initiated	Cowen	Outperform

View All

Adc Therapeutics Sa Stock (ADCT) Latest News

05:01 AM

Will ADC Therapeutics SA stock outperform international peers2026 world cup usa national team round of 32 top scorers high defensive line tactical prediction guide - Улправда

05:01 AM

Jan 03, 2026

ADC Therapeutics Announces New Employee Inducement Grant - 富途牛牛

Jan 03, 2026

Jan 01, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SAADCT - PR Newswire

Jan 01, 2026

Dec 30, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Graphic Packaging Holding Company - GlobeNewswire Inc.

Dec 30, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC ... - Bluefield Daily Telegraph

Dec 30, 2025

Dec 29, 2025

ADC Therapeutics (ADCT) Upgraded to Buy: Here's Why - Yahoo Finance

Dec 29, 2025

Is ADC Therapeutics SA a good long term investmentOptions Trading Strategies & Free Take Advantage Of Momentum - earlytimes.in

Dec 29, 2025

Dec 27, 2025

Corient Private Wealth LLC Makes New Investment in ADC Therapeutics SA $ADCT - MarketBeat

Dec 27, 2025

Dec 19, 2025

Risk Report: Will ADC Therapeutics SA stock beat EPS estimatesQuarterly Profit Report & Fast Gaining Stock Reports - Улправда

Dec 19, 2025

How geopolitical tensions affect ADC Therapeutics SA stockJuly 2025 Analyst Calls & Fast Entry and Exit Trade Plans - Улправда

Dec 19, 2025

Can ADC Therapeutics SA Common Shares stock sustain margin levelsTrade Risk Assessment & Real-Time Stock Entry Alerts - Улправда

Dec 19, 2025

Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines - marketscreener.com

Dec 19, 2025

Is ADC Therapeutics SA stock a contrarian buyJuly 2025 Macro Moves & Fast Gaining Stock Strategy Reports - Улправда

Dec 19, 2025

ADC Therapeutics SA (NYSE:ADCT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Dec 19, 2025

Will ADC Therapeutics SA stock beat EPS estimatesMarket Activity Report & Safe Entry Zone Identification - Улправда

Dec 19, 2025

Is ADC Therapeutics SA Common Shares stock testing key supportJuly 2025 WrapUp & Weekly Stock Breakout Alerts - Улправда

Dec 19, 2025

Dec 18, 2025

Wall Street Recap: Is ADC Therapeutics SA Common Shares stock undervalued historically2025 EndofYear Setup & Weekly High Return Forecasts - Улправда

Dec 18, 2025

How buybacks impact ADC Therapeutics SA stock value2025 Investor Takeaways & Entry and Exit Point Strategies - Улправда

Dec 18, 2025

Is ADC Therapeutics SA Common Shares stock undervalued historically2025 Big Picture & Weekly Momentum Stock Picks - Улправда

Dec 18, 2025

RBC Capital Bullish on ADC Therapeutics S.A. (ADCT) on Lymphoma Treatment Development - Insider Monkey

Dec 18, 2025

Dec 17, 2025

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - sharewise.com

Dec 17, 2025

Dec 15, 2025

ADC Therapeutics (NYSE:ADCT) Sees Large Volume IncreaseStill a Buy? - MarketBeat

Dec 15, 2025